Nordion Announces Completion of Acquisition by Sterigenics International

OTTAWA, Ontario–(BUSINESS WIRE)–Aug. 6, 2014 — Nordion Inc. (TSX:NDN) (NYSE:NDZ), a leading provider of products and services to the global health science market, announced today the successful completion of the previously announced plan of arrangement (the “Arrangement”) and all of the outstanding common shares of Nordion have been acquired by an affiliate of Sterigenics International LLC (“Sterigenics”). Pursuant to the Arrangement, the former holders of Nordion common shares will receive US$13.00 in cash in exchange for each common share held.
“We are extremely excited to welcome the Nordion employees onto the Sterigenics global team,” said Michael Mulhern, CEO of Sterigenics. “We believe this acquisition is transformative in expanding our product and service offerings, broadening our global footprint and allowing us to better serve customers worldwide. Moving forward, Sterigenics is extremely well positioned to build on its mission of improving global public health.”
It is anticipated that the Nordion common shares will be delisted from the Toronto Stock Exchange and from the New York Stock Exchange on or about August 7, 2014.
A registered shareholder must complete and send a letter of transmittal with the certificate(s) representing its common shares to CST Trust Company (the “Depositary”). The Depositary will mail a cheque to the registered shareholder by first class mail as soon as practicable after receipt of the completed letter of transmittal and common share certificate(s). A copy of the letter of transmittal is available under Nordion’s profile on SEDAR at and on EDGAR at
A non-registered shareholder will receive payment through its account with the broker, investment dealer, bank, trust company or other intermediary that holds common shares on its behalf. A non-registered shareholder should contact its intermediary if it has any questions about this process.
About Nordion Inc.
Nordion Inc. (TSX:NDN) (NYSE:NDZ) is a global health science company that provides market-leading products used for the prevention, diagnosis and treatment of disease. We are a leading provider of medical isotopes and sterilization technologies that benefit the lives of millions of people in more than 40 countries around the world. Our products are used daily by pharmaceutical and biotechnology companies, medical-device manufacturers, hospitals, clinics and research laboratories. Nordion has over 400 highly skilled employees in three locations. Find out more at and follow us at
Caution Concerning Forward-Looking Statements
This release contains forward-looking statements, within the meaning of certain securities laws, including under applicable Canadian securities laws and the “safe harbour” provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements relating to our expectations with respect to our beliefs, plans, objectives, expectations, anticipations, estimates and intentions. The words “may”, “will”, “could”, “should”, “would”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”, “project”, “expect”, “intend”, “indicate”, “forecast”, “objective”, “optimistic”, and similar words and expressions are also intended to identify forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release.
Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Additional information on factors that could affect actual results are included in reports on file with applicable securities regulatory authorities, including in our 2013 Annual Information Form (AIF) and our 2014 Management Information Circular. Our 2013 AIF, 2014 Management Information Circular, and our other filings with the Canadian provincial securities commissions and the US Securities and Exchange Commission are available on SEDAR at, on EDGAR at, and on Nordion’s website at
The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. The Company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.
Source: Nordion
Shelley Maclean, 613-592-3400 ext. 2414
[email protected]